Teachers Advisors LLC raised its position in Revance Therapeutics Inc. (NASDAQ:RVNC) by 4.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,535 shares of the biopharmaceutical company’s stock after purchasing an additional 1,620 shares during the quarter. Teachers Advisors LLC owned 0.12% of Revance Therapeutics worth $1,521,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in RVNC. SG Americas Securities LLC purchased a new position in shares of Revance Therapeutics in the 3rd quarter worth about $144,000. Schwab Charles Investment Management Inc. raised its holdings in shares of Revance Therapeutics by 4.9% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 117,258 shares of the biopharmaceutical company’s stock valued at $3,231,000 after buying an additional 5,501 shares during the period. Jennison Associates LLC raised its holdings in shares of Revance Therapeutics by 127.1% during the 4th quarter. Jennison Associates LLC now owns 857,536 shares of the biopharmaceutical company’s stock valued at $30,657,000 after buying an additional 480,008 shares during the period. Victory Capital Management Inc. raised its holdings in shares of Revance Therapeutics by 60.4% during the 4th quarter. Victory Capital Management Inc. now owns 55,685 shares of the biopharmaceutical company’s stock valued at $1,991,000 after buying an additional 20,970 shares during the period. Finally, Alps Advisors Inc. raised its holdings in shares of Revance Therapeutics by 12.9% during the 4th quarter. Alps Advisors Inc. now owns 34,279 shares of the biopharmaceutical company’s stock valued at $1,225,000 after buying an additional 3,928 shares during the period. Institutional investors own 95.01% of the company’s stock.
Several brokerages recently commented on RVNC. Mizuho reiterated a “buy” rating and set a $54.00 target price on shares of Revance Therapeutics in a report on Friday, January 5th. Guggenheim reiterated a “neutral” rating and set a $42.00 target price on shares of Revance Therapeutics in a report on Thursday, January 4th. Cantor Fitzgerald set a $50.00 target price on Revance Therapeutics and gave the company a “buy” rating in a report on Thursday, January 4th. Cowen set a $55.00 target price on Revance Therapeutics and gave the company a “buy” rating in a report on Wednesday, January 17th. Finally, ValuEngine upgraded Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $45.17.
RVNC stock opened at $33.35 on Thursday. Revance Therapeutics Inc. has a 52-week low of $18.42 and a 52-week high of $37.45. The company has a market cap of $1,184.63, a price-to-earnings ratio of -8.32 and a beta of 1.33.
Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.15). Revance Therapeutics had a negative return on equity of 64.40% and a negative net margin of 46,025.57%. The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.09 million. During the same quarter in the prior year, the firm earned ($0.95) earnings per share. Revance Therapeutics’s revenue for the quarter was down 50.7% compared to the same quarter last year. equities analysts anticipate that Revance Therapeutics Inc. will post -3.56 earnings per share for the current fiscal year.
In other Revance Therapeutics news, CFO Lauren P. Silvernail sold 10,000 shares of Revance Therapeutics stock in a transaction that occurred on Wednesday, March 7th. The stock was sold at an average price of $31.50, for a total transaction of $315,000.00. Following the sale, the chief financial officer now directly owns 82,954 shares in the company, valued at approximately $2,613,051. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO L Daniel Browne sold 27,283 shares of Revance Therapeutics stock in a transaction that occurred on Wednesday, March 7th. The stock was sold at an average price of $31.43, for a total value of $857,504.69. Following the sale, the chief executive officer now owns 131,208 shares in the company, valued at $4,123,867.44. The disclosure for this sale can be found here. Insiders have sold a total of 98,366 shares of company stock worth $3,182,947 over the last 90 days. 5.05% of the stock is owned by company insiders.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.